A DOT drug test is a federally regulated urine test that screens for five categories of drugs, currently covering 14 specific substances. It applies to roughly 6.5 million transportation workers in the United States who perform safety-sensitive jobs, including commercial truck drivers, airline crew, railroad employees, transit operators, pipeline workers, and maritime personnel. The test follows strict procedures set by the U.S. Department of Transportation under 49 CFR Part 40, and every step from specimen collection to result verification is standardized nationwide.
The Five Drug Categories and 14 Substances
Although it’s called a “5-panel” test, the DOT panel actually confirms 14 individual substances grouped under five categories:
- Marijuana (THC)
- Cocaine
- Amphetamines: amphetamine, methamphetamine, MDMA (ecstasy), and MDA
- Opioids: codeine, morphine, heroin (tested as 6-AM), hydrocodone, hydromorphone, oxycodone, and oxymorphone
- Phencyclidine (PCP)
The opioid panel was expanded in 2018 to include prescription painkillers like hydrocodone and oxycodone, which were not part of the original testing. This is a notable difference from many private-employer drug tests, which may still use an older panel. Marijuana remains on the DOT panel regardless of state legalization laws. Even if you hold a medical marijuana card, a positive THC result is treated the same as any other positive.
How the Collection Works
DOT specimen collection follows a rigid chain-of-custody process designed to prevent cheating and protect the integrity of the sample. You’ll present a government-issued photo ID at the start. If you don’t have one, the collector contacts your employer to verify your identity before anything proceeds.
Before you provide a sample, the collector secures the restroom: water sources are shut off or taped, blue dye is added to the toilet bowl, and trash cans or ledges where someone might hide adulterants are cleared or secured. You’ll be asked to remove outer clothing like coats, hats, and jackets, empty your pockets, and display everything to the collector. You then wash and dry your hands under observation and cannot wash them again until after the specimen is collected.
You provide the urine sample in private under normal circumstances. Within four minutes of you handing over the cup, the collector checks the temperature (it must be between 90°F and 100°F) and inspects it for unusual color or signs of tampering. The specimen is then split into two vials, sealed with tamper-evident tape, and you initial the seals. If the temperature is out of range or the collector sees signs of tampering, a second collection happens immediately under direct observation by a same-gender observer.
What the Lab Checks Beyond Drugs
The lab doesn’t just test for the five drug categories. It also runs specimen validity testing to catch attempts to beat the test. Three outcomes can flag a problem:
- Dilute: The sample has unusually low creatinine and specific gravity, suggesting the employee drank excessive water to flush their system. A dilute negative may require a retest.
- Substituted: The creatinine and specific gravity are so far outside normal human ranges that the sample isn’t consistent with human urine at all.
- Adulterated: The sample contains a substance that doesn’t naturally occur in urine, or a normal substance at an abnormal concentration, indicating a chemical additive was used.
A substituted or adulterated result is treated the same as a refusal to test, which carries the same consequences as a positive result.
Cutoff Levels for Each Substance
Every DOT drug test uses two rounds of analysis. The initial screening uses a higher threshold to quickly filter out negatives. If a sample triggers that threshold, a more precise confirmatory test is run at a lower cutoff. You only get a positive result if the confirmatory test also exceeds its cutoff. Here are the key thresholds:
- Marijuana (THC): 50 ng/mL initial, 15 ng/mL confirmatory
- Cocaine: 150 ng/mL initial, 100 ng/mL confirmatory
- Amphetamine/Methamphetamine: 500 ng/mL initial, 250 ng/mL confirmatory
- MDMA/MDA: 500 ng/mL initial, 250 ng/mL confirmatory
- Hydrocodone/Hydromorphone: 300 ng/mL initial, 100 ng/mL confirmatory
- Oxycodone/Oxymorphone: 100 ng/mL initial, 100 ng/mL confirmatory
- Codeine/Morphine: 2,000 ng/mL initial, 2,000 ng/mL confirmatory
- Heroin (6-AM): 10 ng/mL initial, 10 ng/mL confirmatory
- PCP: 25 ng/mL initial, 25 ng/mL confirmatory
These thresholds exist so that trace, incidental exposure doesn’t generate false positives. The heroin marker has the lowest cutoff at just 10 ng/mL because the substance it detects (6-acetylmorphine) is uniquely produced by heroin use.
The Medical Review Officer Step
A positive lab result doesn’t go straight to your employer. It first goes to a Medical Review Officer, a licensed physician who acts as an independent gatekeeper. The MRO’s job is to determine whether there’s a legitimate medical explanation for the result. If you have a valid prescription for an opioid painkiller or amphetamine-based medication (like one used for ADHD), the MRO will contact you for an interview, verify your prescription, and can report the test as negative if everything checks out.
The MRO also reviews adulterated, substituted, and invalid results and gives the employee a chance to provide a medical explanation before finalizing the outcome. This step exists specifically to prevent people with legitimate prescriptions from being unfairly flagged.
When You’re Required to Test
DOT drug testing isn’t a one-time event. There are six circumstances that trigger a test:
- Pre-employment: Before you can perform any safety-sensitive function
- Random: Unannounced testing selected by a computer-generated process throughout the year
- Post-accident: After certain qualifying accidents
- Reasonable suspicion: When a trained supervisor observes signs of drug use
- Return-to-duty: Before returning to work after a violation
- Follow-up: After completing the return-to-duty process, for a period determined by a Substance Abuse Professional
What Counts as a Refusal
Refusing a DOT drug test carries the same consequences as testing positive, and “refusal” covers more than just saying no. You’ve legally refused if you fail to show up within a reasonable time after being notified, leave the collection site before the process is complete, fail to provide a specimen, refuse to allow direct observation when it’s required, or fail to undergo a medical evaluation directed by the MRO. Even failing to provide enough urine counts as a refusal if a medical evaluation determines there’s no physical reason you couldn’t produce a sufficient sample.
What Happens After a Positive Result
If your test comes back positive (or you refuse), you’re immediately prohibited from performing any safety-sensitive duties. The violation is recorded in the FMCSA Drug and Alcohol Clearinghouse for commercial driver positions, and you cannot return to work until you complete the full Return-to-Duty process in a specific order.
First, your employer provides a list of DOT-qualified Substance Abuse Professionals (SAPs). You select one, and the SAP conducts an initial evaluation to determine what education or treatment you need. After you complete that program, the SAP re-evaluates you, confirms compliance, and establishes a follow-up testing plan. Only then can you take a return-to-duty test, and only a negative result on that test allows you to resume safety-sensitive work. Follow-up testing continues for a period the SAP determines, with a minimum of six direct-observation tests in the first 12 months.
Oral Fluid Testing Is Coming
As of December 2024, the DOT finalized rules allowing oral fluid (saliva) testing as an alternative to urine. The infrastructure isn’t fully operational yet because the Department of Health and Human Services must first certify oral fluid testing laboratories, but the regulatory framework is in place. Once labs are certified, employers will have the option to use either urine or oral fluid for DOT testing. Oral fluid collection requires its own separately trained collectors and follows different procedures, though the same five drug categories will be tested. This change is expected to make observed collections less invasive and reduce opportunities for specimen substitution.